Literature DB >> 2154437

Comparison of the acid stability of azithromycin and erythromycin A.

E F Fiese1, S H Steffen.   

Abstract

In acidic aqueous media, erythromycin A is rapidly degraded via intramolecular dehydration to form erythromycin-6.9-hemiketal and then anhydroerythromycin, both of which possess little antimicrobial activity. Azithromycin, a new azalide antibiotic, has a methyl-substituted nitrogen in place of the carbonyl at the 9a position of the aglycone ring, thus blocking the internal dehydration pathway. As a result, azithromycin decomposition occurs primarily via acid-catalysed hydrolysis of the ether bond to the neutral cladinose sugar. Rate constants and the time for 10% decay (T1/10) were determined for both azithromycin and erythromycin A at pH2 using various levels of acetonitrile cosolvent and constant ionic strength. Semi-log plots of the decay rate constants versus the reciprocal of the solution dielectric constants were used to extrapolate to totally aqueous conditions. In solution at 37 degrees C and pH2 with ionic strength mu = 0.02, azithromycin was degraded with a T1/10 of 20.1 min while erythromycin underwent 10% decay in only 3.7 sec. The activation energy for hydrolysis of the ether bond connecting cladinose to azithromycin was 25.3 kcal/mol while the internal dehydration reaction of erythromycin had an activation energy of 15.6 kcal/mol. A solution stability profile was generated for azithromycin over the pH range of 1.0 to 4.1 at 30 degrees C. Stability was found to improve ten-fold for each unit increase in pH.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154437     DOI: 10.1093/jac/25.suppl_a.39

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  38 in total

1.  In vitro metabolism and stability of the actinide chelating agent 3,4,3-LI(1,2-HOPO).

Authors:  Taylor A Choi; Anna M Furimsky; Robert Swezey; Deborah I Bunin; Patricia Byrge; Lalitha V Iyer; Polly Y Chang; Rebecca J Abergel
Journal:  J Pharm Sci       Date:  2015-02-27       Impact factor: 3.534

2.  Efficacy of cethromycin, a new ketolide, against Streptococcus pneumoniae susceptible or resistant to erythromycin in a murine pneumonia model.

Authors:  E Azoulay-Dupuis; J Mohler; J P Bédos; C Barau; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  The oligo-acyl lysyl antimicrobial peptide C₁₂K-2β₁₂ exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori.

Authors:  Morris O Makobongo; Hanan Gancz; Beth M Carpenter; Dennis P McDaniel; D Scott Merrell
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

4.  Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling.

Authors:  Hannah M Jones; Neil Parrott; Gerd Ohlenbusch; Thierry Lavé
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics.

Authors:  Alison E Fohner; Alex Sparreboom; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-04       Impact factor: 2.089

Review 6.  The pharmacokinetics of azithromycin and their clinical significance.

Authors:  H Lode
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

7.  Gynaecological tissue levels of azithromycin.

Authors:  K Krohn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

8.  Concentrations of azithromycin in human tonsillar tissue.

Authors:  G Foulds; K H Chan; J T Johnson; R M Shepard; R B Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

9.  Effects of environmental factors on the in vitro potency of azithromycin.

Authors:  J A Retsema; L A Brennan; A E Girard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

10.  Azithromycin concentrations in sinus fluid and mucosa after oral administration.

Authors:  P Karma; J Pukander; M Penttilä
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.